Lhasa Limited shared knowledge shared progress
  • Publisher:
  • Publication Date:
    Oct 2014
  • Reference:
  • DOI:
  • PMID:
  • Publication Type:
  • Related Products:
  • Scientific Area:
  • Endpoint:
  • Industry Type:
  • Related event:

Setting-up of an internal multidisciplinary Vehicle Working Group to increase knowledge on excipients and recommend their use in preclinical in vivo studies

pdf fileBerwaer M; Briône W; Caruso M; Cauvin A; Chaussée C; De Ron P; Delaunois A; Fallah-Arani F; Martin F; Van Asperen J;

This poster explores UCB's implementation of a Vehicle Working Group to increase internal knowledge on excipients and recommend use in preclinical studies. But why is this important?

  • Enabling formulations for preclinical in vivo studies play a key role for assessing safety, pharmacodynamics, and pharmacokinetics (PK) endpoints of new molecules.
  • Excipients used in formulations should maximize exposure while avoiding side effects that could influence experimental results
  • As new chemical entities are not always sufficiently soluble and/or bioavailable in commonly used vehicles, ‘exotic cocktails’ of various excipients are often used to prepare preclinical formulations
  • Limited information has been published on the potential impact of these excipients on commonly used laboratory animals.


Poster present by Annie Delaunois at the 2014 Safety Pharmacology Society Meeting, Washington, USA; 19th - 22nd October 2014.


Related Publications

© 2019 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Thanks to QuestionPro's generosity, we now have survey software that powers our data intelligence.